Commentary

Podcast

Pharmacy Focus: Oncology Edition - PARP Inhibitors in Ovarian Cancer

Kirollos Hanna, PharmD, BCPS, BCOP, discussed how PARP inhibitors have changed the treatment landscape of ovarian cancer.

In the second episode of Pharmacy Focus: Oncology Edition, Kirollos Hanna, PharmD, BCPS, BCOP, discussed how PARP inhibitors have changed the treatment landscape of ovarian cancer.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Related Content
Computer Screen in Hospital Radiology Room: Woman Standing Undergoing Mammography Screening Procedure. Screen Showing the Mammogram Scans of Dense Breast Tissues - Image credit: Gorodenkoff | stock.adobe.com
September 3rd 2025

Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk Early Breast Cancer

Kennedy Ferruggia, Assistant Editor
Pharmacy Focus Oncology Edition Podcast
September 3rd 2025

Protecting Community Oncology Practices in the Wake of the IRA

Alexandra Gerlach, Associate Editor
Close up of prostate cancer cells - Image credit: Science RF | stock.adobe.com
September 3rd 2025

FDA Approves 3-Month Leuprolide Mesylate 21-mg Formulation for Advanced Prostate Cancer

Kennedy Ferruggia, Assistant Editor
From Guidelines to Action: Pharmacy’s Role in Hypertension Management
September 3rd 2025

From Guidelines to Action: Pharmacy’s Role in Hypertension Management

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
Breast cancer cells | Image Credit: © sknab - stock.adobe.com
September 3rd 2025

Abemaciclib Plus Endocrine Therapy Improves Survival in Patients With HR+/HER2– Breast Cancer

Alexandra Gerlach, Associate Editor
Breast cancer and SERDs -- Image credit: Phongsakorn | stock.adobe.com
September 3rd 2025

Oral SERDs in Breast Cancer: Imulnestrant and Elacestrant

Gillian McGovern, Associate Editor
© 2025 MJH Life Sciences

All rights reserved.